SCHEMBL5067508

SCHEMBL5067508

COC(=O)c1ccc(CN(C)C)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.61
TSHR P16473 2/20 0.57
KDM4E B2RXH2 1/20 0.57
NPC1 O15118 1/20 0.57
ALDH1A1 P00352 1/20 0.57
GAA P10253 1/20 0.57
HPGD P15428 1/20 0.57
MAPK1 P28482 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
HSD17B10 Q99714 1/20 0.57
CYP4A11 Q02928 2/20 0.56
CYP4F2 P78329 1/20 0.54
RAB9A P51151 1/20 0.54
CA1 P00915 3/20 0.53
CA2 P00918 3/20 0.53
TDP1 Q9NUW8 1/20 0.53
CA12 O43570 1/20 0.53
CA7 P43166 1/20 0.53
CA9 Q16790 1/20 0.53
CA14 Q9ULX7 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7376896 0.92 LOXL2 (0.53) LOXL2TSHRKDM4ENPC1ALDH1A1
SCHEMBL8781971 0.87 LOXL2 (0.59) LOXL2TSHRKDM4ENPC1ALDH1A1
SCHEMBL5507533 0.85 LOXL2 (0.61) LOXL2TSHRKDM4ENPC1ALDH1A1
SCHEMBL23423391 0.84 LOXL2 (0.56) LOXL2TSHRKDM4ENPC1ALDH1A1
Hydrochloric Acid SCHEMBL5983459 0.83 LOXL2 (0.59) LOXL2TSHRKDM4ENPC1ALDH1A1
SCHEMBL13052122 0.82 ACHE (0.66) LOXL2TSHRKDM4ENPC1ALDH1A1
SCHEMBL5185961 0.81 LOXL2 (0.58) LOXL2TSHRKDM4ENPC1ALDH1A1
SCHEMBL15329199 0.81 CYP4A11 (0.62) LOXL2TSHRKDM4ENPC1ALDH1A1
SCHEMBL5068516 0.81 HDAC8 (0.65) LOXL2TSHRKDM4ENPC1ALDH1A1
SCHEMBL5642409 0.81 LOXL2 (0.58) LOXL2TSHRKDM4ENPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7001973-B2 Catalyst and process for preparing low-viscosity and color-reduced polyisocyanates containing isocyanurate groups DEGUSSA AG (DE) 2006-02-21 US claimed
US-20030187178-A1 Catalyst and process for preparing low-viscosity and color-reduced polyisocyanates containing isocyanurate groups DEGUSSA AG (DE) 2003-10-02 US claimed
US-6613863-B2 Benzyltrialkylammonium carboxylate isocyanate trimerization catalysts DEGUSSA AG (DE) 2003-09-02 US claimed
US-20020120089-A1 Catalyst and process for preparing low-viscosity and color-reduced polyisocyanates containing isocyanurate groups DEGUSSA AG (DE) 2002-08-29 US claimed
CN-119432425-A Demulsifier special for desalting heavy fuel oil for gas turbine and preparation method thereof 佛山市天辰洁能环保技术有限公司 2025-02-14 CN disclosed
US-20230152692-A1 CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-05-18 US disclosed
US-9421532-B2 Mononuclear iron complex and organic synthesis reaction using same KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2016-08-23 US disclosed
US-9421532-B2 Mononuclear iron complex and organic synthesis reaction using same KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2016-08-23 US disclosed
US-20160023196-A1 MONONUCLEAR IRON COMPLEX AND ORGANIC SYNTHESIS REACTION USING SAME SHIN-ETSU CHEMICAL CO., LTD. (JP) 2016-01-28 US disclosed
US-20140073627-A1 BRADYKININ B1 ANTAGONISTS EVOTEC AG (DE) 2014-03-13 US disclosed
US-8623859-B2 Bradykinin B1 antagonists EVOTEC AG (DE) 2014-01-07 US disclosed
US-20110201589-A1 NEW BRADYKININ B1 ANTAGONISTS EVOTEC AG (DE) 2011-08-18 US disclosed
US-6232342-B1 CATHEPSIN K INHIBITOR FOR TREATING OSTEOPOROSIS, GINGIVITIS, PERIODONTITIS, ARTHRITIS, OSTEOARTHRITIS RHEUMATOID ARTHRITIS, PAGET'S DISEASE, HYPERCALCEMIA OF MALIGNANCY AND METABOLIC BONE DISEASES SMITHKLINE BEECHAM CORPORATION 2001-05-15 US disclosed
EP-1085030-A2 Catalyst and process for preparing polyisocyanates having isocyanurate groups and low colouring Degussa-Hüls Aktiengesellschaft (DE) 2001-03-21 EP disclosed
EP-1019046-A1 PROTEASE INHIBITORS Smithkline Beecham (US) 2000-07-19 EP disclosed
US-6057362-A Protease inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2000-05-02 US disclosed
US-5998470-A Protease inhibitors SMITHKLINE BEECHAM CORPORATION (US) 1999-12-07 US disclosed
EP-0914319-A1 DIARYLALKYL CYCLIC DIAMINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS TEIJIN LIMITED (JP) 1999-05-12 EP disclosed
WO-1998048799-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1998-11-05 WO disclosed
WO-1997044329-A1 DIARYLALKYL CYCLIC DIAMINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS TEIJIN LIMITED (JP) 1997-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160023196-A1 MONONUCLEAR IRON COMPLEX AND ORGANIC SYNTHESIS REACTION USING SAME HNRNPL, ACSL3, RBCK1 LOXL2 88/4885TSHR 2029/4885KDM4E 1810/4885
US-20140073627-A1 BRADYKININ B1 ANTAGONISTS BDKRB1, BDKRB2, BRS3 LOXL2 2034/4885TSHR 962/4885KDM4E 2806/4885
US-20110201589-A1 NEW BRADYKININ B1 ANTAGONISTS BDKRB1, BDKRB2, BRS3 LOXL2 2093/4885TSHR 1030/4885KDM4E 2968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.